Bradley M. Thompson, Member of the Firm, joins a panel discussion, “Mobile Medical Applications: FDA & FTC Issues,” at FDLI’s Advertising & Promotion Conference, which runs from October 1 to 2.
Because the definition of a medical device depends on its intended use, which is established through labeling, advertising, and statements by the manufacturer, it is critical that companies exercise care when promoting products. Even if a device is low risk, the FTC retains the authority to take enforcement action for false or misleading claims. In this session, panelists will discuss the special considerations posed by the availability and promotion of mobile medical applications.
For more information, visit FDLI.org.